멀티모달 이미징 시장 : 모달리티 조합해별, 기술별, 워크플로우 단계별, 휴대성별, 용도별 예측(2026-2032년)

The Multimodal Imaging Market is projected to grow by USD 7.64 billion at a CAGR of 7.49% by 2032.

Multimodal imaging is moving from a specialized diagnostic capability to a core pillar of precision medicine, combining modalities such as PET/CT, SPECT/CT, PET/MRI, ultrasound, optical imaging, fluorescence imaging, and advanced digital pathology to produce a more complete view of anatomy, physiology, metabolism, perfusion, and molecular activity. Demand is supported by verified disease-burden indicators: the World Health Organization reported approximately 20 million new cancer cases and 9.7 million cancer deaths in 2022, while cardiovascular diseases remain the leading cause of death globally, responsible for an estimated 17.9 million deaths each year.

For healthcare providers, the strategic value of multimodal imaging lies in earlier detection, more accurate staging, treatment planning, image-guided intervention, therapy response assessment, and longitudinal monitoring. As health systems prioritize outcomes, productivity, dose management, and patient-centric care, integrated imaging platforms and AI-enabled workflows are becoming essential to radiology, oncology, neurology, cardiology, and surgical service lines.

Transformative Shifts in the Imaging Landscape

The multimodal imaging landscape is being reshaped by convergence across imaging hardware, software, radiopharmaceuticals, cloud infrastructure, picture archiving and communication systems, pathology platforms, and clinical decision support. Hybrid systems such as PET/CT and SPECT/CT are embedded in oncology and cardiology pathways, while PET/MRI, quantitative MRI, photoacoustic imaging, and molecular imaging are gaining relevance in neuroimaging, prostate cancer, musculoskeletal care, inflammatory disease, and pediatric applications where radiation management is a priority.

A second shift is operational. Imaging departments are under pressure from rising exam volumes, workforce shortages, and demand for faster turnaround. OECD and national health-system reporting consistently show high utilization of CT and MRI in advanced healthcare systems, while many emerging economies are expanding diagnostic capacity to close access gaps. This is accelerating investment in automation, interoperability, vendor-neutral archives, structured reporting, enterprise imaging, and remote collaboration. The competitive focus is no longer only image quality; it is also workflow efficiency, dose optimization, data integration, clinical standardization, and measurable patient impact.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across multimodal imaging by improving acquisition, reconstruction, noise reduction, segmentation, triage, quantification, lesion tracking, and reporting. In clinical practice, AI tools are increasingly used to prioritize suspected stroke, pulmonary embolism, intracranial hemorrhage, fractures, breast lesions, and lung nodules, while research applications are expanding into radiomics, digital biomarkers, survival-risk stratification, and therapy response prediction.

The strongest value emerges when AI connects information across modalities rather than analyzing images in isolation. Combining CT anatomy, PET metabolism, MRI tissue characterization, ultrasound dynamics, pathology, genomics, laboratory data, and electronic health record information can support more precise diagnosis and personalized treatment selection. However, adoption depends on clinical validation, external testing, bias monitoring, cybersecurity, explainability, clinician oversight, and compliance with applicable FDA requirements, EU MDR, HIPAA, GDPR, and emerging AI governance frameworks.

Key Regional Insights for Multimodal Imaging

North America remains a leading region for multimodal imaging adoption because of advanced hospital infrastructure, high use of cross-sectional imaging, mature nuclear medicine capabilities, strong academic research networks, and active regulatory review of imaging AI software. The United States and Canada also benefit from established cancer centers and structured quality programs, although payer scrutiny and workforce capacity continue to influence purchasing and deployment decisions. Europe benefits from universal or publicly supported healthcare systems, EU research initiatives, strong radiology societies, and clinical standardization across oncology, cardiology, and neurology, while EU MDR compliance and public procurement cycles can extend commercialization timelines.

Asia-Pacific is one of the most dynamic regions for multimodal imaging because cancer screening, tertiary hospital modernization, digital health investment, and aging-population needs are rising across China, India, Japan, South Korea, and Australia. Latin America is advancing through private hospital networks, oncology investments, and diagnostic-center expansion, particularly in Brazil and Mexico, although uneven reimbursement and infrastructure access remain constraints. The Middle East is investing in specialty hospitals, diagnostic hubs, and national health transformation programs, especially in GCC countries, while Africa shows long-term potential as public-private partnerships, donor-backed health programs, teleradiology, and training initiatives address shortages in radiology infrastructure, nuclear medicine access, and specialist availability.

Key Group Insights Across Global Health Economies

ASEAN demand is supported by urban hospital expansion, medical tourism, and rising noncommunicable disease prevalence, with Singapore acting as a regional hub for advanced care, Thailand and Malaysia strengthening medical travel, and Indonesia, Vietnam, and the Philippines expanding access through public and private investment. GCC healthcare systems are advancing rapidly through national health transformation programs, premium hospital construction, digital health strategies, and interest in oncology, cardiology, trauma care, and AI-enabled diagnostics.

The European Union is an important center for regulated innovation, cross-border research, clinical standardization, and health data governance, particularly in cancer imaging, neurodegenerative disease, and radiation safety. BRICS countries offer scale and long-term demand, led by China and India's hospital expansion, Brazil's private diagnostics sector, Russia's domestic diagnostic needs, and South Africa's role as a regional healthcare hub. G7 markets account for a major portion of high-end imaging utilization, peer-reviewed research output, guideline development, and regulatory influence, while NATO countries increasingly emphasize resilient health systems, trauma readiness, cybersecurity, interoperable medical technology infrastructure, and secure data exchange.

Key Country Insights Shaping Market Demand

The United States leads in commercialization, AI imaging authorizations, nuclear medicine infrastructure, academic research, and clinical trial activity, while Canada emphasizes equitable access, public reimbursement, evidence-based procurement, and pan-provincial coordination. Mexico and Brazil are strengthening private diagnostics, hospital chains, and oncology capacity, although access differences between urban and rural populations remain material and continue to shape deployment priorities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain anchor demand through mature hospital networks, national cancer programs, radiology modernization, and aging-population needs; Germany is especially relevant for engineering depth, imaging manufacturing capability, and clinical research. Russia has domestic demand for advanced diagnostics but faces technology-access constraints and procurement limitations. In Asia-Pacific, China is scaling imaging capacity and oncology infrastructure, India is expanding tertiary care, diagnostic chains, and public health coverage, Japan maintains high imaging density and strong demand linked to population aging, South Korea is strong in digital health, semiconductor-enabled medical technology, and hospital innovation, and Australia combines advanced clinical adoption with strong research governance and national quality standards.

Actionable Recommendations for Industry Leaders

Healthcare leaders should prioritize multimodal imaging investments that address defined clinical pathways rather than isolated equipment upgrades. Oncology, stroke, cardiovascular disease, neurodegeneration, musculoskeletal disorders, inflammatory disease, and image-guided therapy provide strong use cases because integrated imaging can improve diagnosis, staging, treatment selection, procedure planning, and follow-up.

Executives should build enterprise imaging strategies around interoperability, cybersecurity, AI governance, data quality, workforce productivity, and clinical accountability. Practical steps include standardizing acquisition protocols, expanding structured reporting, integrating radiology and pathology workflows, validating AI across local populations, strengthening radiology-nuclear medicine collaboration, improving radiopharmaceutical logistics, and measuring outcomes such as turnaround time, repeat-scan reduction, diagnostic confidence, report consistency, radiation-dose optimization, patient throughput, and downstream cost avoidance.

Research Methodology and Data Validation

This executive summary is based on secondary research from verified public and institutional sources, including the World Health Organization, International Agency for Research on Cancer, OECD health statistics, national regulatory agencies, peer-reviewed medical literature, clinical guideline bodies, and publicly available hospital, academic, and regulatory disclosures. The analysis triangulates disease burden, technology adoption, reimbursement signals, regulatory activity, infrastructure readiness, clinical workflow trends, and digital health governance.

The methodology applies a structured market-intelligence approach that combines data validation, source cross-checking, regional assessment, and expert interpretation. Insights are presented to support strategic decision-making across providers, medical technology suppliers, investors, policymakers, and healthcare stakeholders while avoiding unsupported claims, unverified assumptions, market sizing, market share, or forecasting statements.

Conclusion: Strategic Outlook for Multimodal Imaging

Multimodal imaging is becoming a strategic enabler of precision diagnostics, combining complementary imaging data with AI-enabled interpretation to improve clinical confidence, workflow efficiency, and care coordination. Demand is underpinned by cancer, cardiovascular disease, neurological disorders, aging populations, expanding screening programs, and the shift toward personalized treatment.

The next phase of competition will favor organizations that integrate imaging platforms, analytics, clinical workflows, data governance, and evidence generation. Providers and technology stakeholders that align adoption with measurable outcomes, regulatory compliance, cybersecurity, workforce support, and patient access will be best positioned to create durable value in the evolving multimodal imaging market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multimodal Imaging Market, by Modality Combination

• 7.1. PET/CT
• 7.2. SPECT/CT
• 7.3. PET/MRI
• 7.4. Optical + MRI / CT
• 7.5. Ultrasound + CT / MRI

8. Multimodal Imaging Market, by Technology

• 8.1. Nuclear Imaging Technologies
• 8.2. Structural Imaging Technologies
• 8.3. Optical Imaging

9. Multimodal Imaging Market, by Workflow Stage

• 9.1. Preclinical Imaging
• 9.2. Clinical Imaging

10. Multimodal Imaging Market, by Portability

• 10.1. Fixed Systems
• 10.2. Mobile Imaging Systems

11. Multimodal Imaging Market, by Application

• 11.1. Oncology
• 11.2. Cardiology
• 11.3. Neurology
• 11.4. Orthopedics
• 11.5. Infectious Diseases

12. Multimodal Imaging Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Multimodal Imaging Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Multimodal Imaging Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agfa-Gevaert Group
• 16.2. Bruker Corporation
• 16.3. Canon Medical Systems Corporation
• 16.4. Carestream Health, Inc.
• 16.5. Cubresa Inc.
• 16.6. Esaote S.p.A.
• 16.7. Fujifilm Holdings Corporation
• 16.8. GE HealthCare Technologies Inc.
• 16.9. Hitachi, Ltd.
• 16.10. Hologic, Inc.
• 16.11. Koninklijke Philips N.V.
• 16.12. Mediso Ltd.
• 16.13. MR Solutions Group Ltd.
• 16.14. Neusoft Medical Systems Co., Ltd.
• 16.15. Positron Corporation
• 16.16. Shimadzu Corporation
• 16.17. Siemens Healthineers AG
• 16.18. Sofie Biosciences, Inc.
• 16.19. United Imaging Healthcare Co., Ltd.